Shuang Liu, PhD, Founder & CEO Co-inventor of CSTI-500. 20 years of experience in drug R&D as integrated project leader. Led AMRI’s triple monoamine program which led to a multiple-year productive collaboration with BMS that delivered 4 NCEs, including CSTI-500, for clinical development. Led other successful discovery programs in CNS, oncology and autoimmune at AMRI. Co-Inventor of >30 patent families. PhD in organic Chemistry from University of Georgia with postdoc training at Emory University.
John Maki, COO & Acting President 30 years of management and investment experience in life science. Formerly CEO of Vicus Therapeutics a clinical stage immuno-oncology company, Managing Director at TDI and Audax Group, Principal at Bain Capital and Consultant at Bain & Company. Mr. Maki serves on the boards of Vicus Therapeutics and 3DMatrix as well as the Board of Trustees of BIO NJ. AB in Economics from Harvard University.
Martin Bexon, MD, Contract Medical & Regulatory Affairs 15 years of experience in clinical development and medical affairs. Former Global Medical Director for rare diseases at CSL Behring and International Medical Leader at Roche.
Lois Rosenberger, PhD, Contract Regulatory and Clinical Operations Management President of LBR Regulatory and Clinical Consulting Services. 30+ years of regulatory, quality assurance and 20+ years of experience in managing clinical trials including for PWS. Lois held regulatory leadership positions at Kendle CRO, Marion-Merrell Dow and P&G.
Allen Ritter, PhD, Contract CMC 30 years of experience in the development, manufacturing, outsource manufacturing, and registration of pharmaceuticals. Former VP Manufacturing/CMC at Endocyte and CMC/QA management positions at Eli Lilly.
Shayne Gad, PhD, DABT, Contract Toxicology Founder of Gad Consulting Services. 40 years of board-based experience in toxicology. A past president of the American College of Toxicology (ACT) and the recipient of the 2008 ACT Lifetime Achievement Award.